Tango Therapeutics (TNGX) Corporate presentation summary

Pipeline and clinical development

• Advancing a robust pipeline targeting MTAP-deleted cancers, including vopimetostat (PRMT5 inhibitor), TNG456 (brain-penetrant PRMT5 inhibitor), TNG961 (HBS1L degrader), and TNG260 (COREST inhibitor) across multiple solid tumor indications, with several programs in phase 1/2 or IND-enabling stages.

• Vopimetostat demonstrated a 27% ORR and 6.4-month mPFS across 16 histologies, with a 25% ORR and 7.2-month mPFS in 2L pancreatic cancer, outperforming historical standards of care.

• TNG456 is in phase 1/2 for glioblastoma, showing strong brain penetrance and potency, with FDA Fast Track and Orphan Drug designations.

• TNG260, a COREST inhibitor, restored checkpoint inhibitor responsiveness in STK11-mutant lung cancer, with early proof-of-concept data showing mPFS of 6.7 months in combination with pembrolizumab.

• TNG961, a selective HBS1L degrader, is IND-ready for FOCAD/MTAP-deleted solid tumors, with strong preclinical efficacy and a clean safety profile.

Strategic execution and competitive positioning

• Launching a pivotal phase 3 study for vopimetostat in 2L MTAP-deleted pancreatic cancer in 2026, with FDA support for the protocol and rapid enrollment anticipated.

• Expanding vopimetostat data in lung and other cancers to support additional pivotal studies, and evaluating efficacy in glioblastoma with TNG456.

• Vopimetostat is the first PRMT5 inhibitor in clinical combination with RAS inhibitors, aiming for innovative, chemo-sparing regimens in front-line pancreatic cancer.

• Histology-selective cohort showed a 49% ORR and 9.1-month mPFS, more than doubling historical controls in multiple late-line cancers.

• Vopimetostat and TNG456 selectively target MTAP-deleted cells, sparing normal tissue and supporting a favorable safety profile.

Financial highlights and outlook

• Raised $225M in equity, with a cash balance of $343M as of December 31, 2025, providing a projected cash runway into 2028.

• Multiple key clinical milestones expected in 2026, including pivotal study initiations and data readouts for vopimetostat, TNG456, and combination studies.

• Strong balance sheet supports continued advancement of the pipeline and strategic execution.